The Problem of Non-Response and the Promise of Precision
Conventional psychiatric medication is often a protracted process of trial and error. A patient with depression may try multiple SSRIs, each taking weeks to show effect, only to experience insufficient relief or debilitating side effects. This one-size-fits-all approach is inefficient and discouraging. The field of pharmacogenomics—the study of how genes affect a person's response to drugs—offers a path toward precision. The Institute's Personalized Psychopharmacology Program is building a comprehensive database linking genetic variants to responses across the spectrum of psychotropic substances, from classic antidepressants to psychedelics, aiming to create genetically-informed treatment algorithms.
Key Genetic Variants Influencing Drug Response
Our research focuses on several key classes of genes. First are genes encoding drug-metabolizing enzymes, particularly the cytochrome P450 (CYP) family. Variations in genes like CYP2D6, CYP2C19, and CYP3A4 determine whether someone is a poor, intermediate, extensive, or ultra-rapid metabolizer of a given drug. For example, a poor metabolizer of a tricyclic antidepressant will have dangerously high blood levels at a standard dose, while an ultra-rapid metabolizer may see no benefit. We genotype patients for these variants to guide initial dosing.
Second are genes encoding the drug targets themselves—the receptors and transporters. Polymorphisms in the serotonin transporter gene (SLC6A4), such as the 5-HTTLPR, influence baseline serotonin reuptake efficiency and predict differential response to SSRIs. Variants in the serotonin 2A receptor gene (HTR2A) are associated with the intensity of subjective effects and potentially the therapeutic efficacy of psychedelics like psilocybin. Third, we study genes involved in downstream signaling pathways and neuroplasticity, such as those for BDNF (Brain-Derived Neurotrophic Factor) and its receptor TrkB, which may predict who is most likely to experience the neuroregenerative effects of certain treatments.
Implementing a Genetically-Guided Framework
Our clinical protocol involves a pre-treatment genetic panel. The results are fed into a decision-support algorithm that weighs the evidence for each variant's impact on pharmacokinetics (how the body handles the drug) and pharmacodynamics (what the drug does to the body). The output is a personalized report for the clinician. It might recommend: "Based on CYP2C19 poor metabolizer status, consider a 50% lower starting dose of citalopram and monitor for side effects," or "Presence of the Met/Met BDNF Val66Met polymorphism suggests reduced activity-dependent BDNF secretion; consider augmentation with a psychoplastogen or lifestyle intervention known to boost BDNF."
For psychedelic-assisted therapy, a genetic profile might help in participant selection and preparation. Someone with a genetic predisposition for high anxiety or psychosis might be counseled differently or steered toward a non-hallucinogenic alternative. We are also conducting prospective trials to validate these approaches, randomizing patients to receive either treatment-as-usual or genetically-guided therapy. Early data shows the genetic-guided group achieves remission faster and with fewer medication switches. The goal is a future where a simple cheek swab can guide a patient and doctor to the most promising treatment from the start, transforming psychopharmacology from a guessing game into a precise, personalized science, reducing suffering and accelerating recovery.